T. Shirakata

发表

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2006, Japanese journal of clinical oncology.

Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.

Y. Doki, M. Mori, K. Aozasa, 2009, International journal of oncology.

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies

I. Kawase, S. Morita, Toshinori Ito, 2019, Medicine.

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

T. Kyo, H. Dohy, I. Kawase, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a WT1 protein‐derived peptide, WT1187, as a HLA‐A*0206‐restricted, WT1‐specific CTL epitope

I. Kawase, N. Hosen, Y. Oji, 2008, Microbiology and immunology.

A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells

I. Kawase, Y. Oji, A. Tsuboi, 2008, Microbiology and immunology.

Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.

Y. Oji, A. Tsuboi, Y. Oka, 2008, International journal of oncology.

Wilms’ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro

N. Hosen, Y. Oji, M. Kawakami, 2006, Cancer science.

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

J. Sakamoto, E. Morii, S. Morita, 2018, International journal of cancer.

with the Wilms tumor gene, WT1 AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation

I. Kawase, K. Aozasa, N. Hosen, 2012 .

AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.

I. Kawase, K. Aozasa, N. Hosen, 2006, Blood.

AML 1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene , WT 1

I. Kawase, K. Aozasa, N. Hosen, 2006 .

Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

I. Kawase, N. Hosen, Y. Oji, 2012, Vaccine.

Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors

Toshiki Yoshimine, Sumiyuki Nishida, Motohiko Maruno, 2004, Cancer science.

WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor

S. Miyoshi, I. Kawase, K. Aozasa, 2009, International journal of cancer.

Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.

J. Melenhorst, E. Gostick, H. Shiku, 2012, Blood.

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2008, Journal of neurosurgery.

Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38− cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells

I. Kawase, N. Hosen, Y. Sonoda, 2004, Leukemia.

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

J. Sakamoto, T. Enomoto, S. Morita, 2013, Journal of Cancer Research and Clinical Oncology.

WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma

T. Shuin, Y. Ohtsuki, T. Takeuchi, 2007, Microbiology and immunology.

The Wilms’ tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis

I. Weissman, M. Okabe, N. Hosen, 2007, Leukemia.

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

H. Shiku, H. Fujiwara, K. Kuzushima, 2011, Blood.

WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.

I. Kawase, N. Hosen, Y. Oji, 2009, Anti-cancer agents in medicinal chemistry.

Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 µg/Body) in a Patient with Chronic Myelomonocytic Leukemia

J. Sakamoto, I. Kawase, S. Morita, 2007 .

High frequencies of less differentiated and more proliferative WT1‐specific CD8+ T cells in bone marrow in tumor‐bearing patients: An important role of bone marrow as a secondary lymphoid organ

I. Kawase, T. Enomoto, T. Ueda, 2010, Cancer science.

WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.

H. Inohara, N. Hosen, Y. Oji, 2012, Anticancer research.

WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient

J. Sakamoto, I. Kawase, Toshio Tanaka, 2010, European journal of haematology.

A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.

Y. Takeda, T. Yoshimine, I. Kawase, 2010, Anticancer research.

Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8+ T cells in patients with myeloid malignancies

Y. Kanda, I. Kawase, N. Hosen, 2010, Cancer science.

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers

I. Kawase, N. Hosen, Y. Oji, 2007, TheScientificWorldJournal.

Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway

M. Asada, Y. Tsujimoto, S. Shimizu, 2006, Oncogene.

"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.

I. Kawase, N. Hosen, Y. Oji, 2008, Current medicinal chemistry.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

T. Enomoto, S. Morita, N. Hosen, 2021, Journal of immunotherapy.

Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.

J. Sakamoto, I. Kawase, S. Morita, 2007, International journal of hematology.

Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

Identification of a gene element essential for leukemia-specific expression of transgenes

I. Kawase, N. Hosen, Y. Oji, 2004, Leukemia.

Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

J. Sakamoto, A. Ogata, I. Kawase, 2007, International journal of hematology.

Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.

M. Yano, M. Monden, Y. Fujiwara, 2004, Anticancer research.

The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver.

N. Hosen, Y. Oji, M. Kawakami, 2005, Biochemical and biophysical research communications.

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

J. Hatazawa, T. Yoshimine, J. Sakamoto, 2008, Journal of neurosurgery.

High frequencies of less differentiated and more proliferative WT1‐specific CD8+ T cells in bone marrow in tumor‐bearing patients: An important role of bone marrow as a secondary lymphoid organ

I. Kawase, T. Enomoto, T. Ueda, 2010, Cancer science.